

ember 2009, 11 recurrent/refractory patients (10 MMGCT, 1 germinoma; 10 males; mean age 16.5 years, range 7–46 years) have been treated with up to four cycles of gemcitabine (800mg/M2), paclitaxel (170mg/M2) and oxaliplatin (100mg/M2) administered on one day at 14 days intervals. RESULTS: All 11 patients were enrolled on a prospective multicenter trial, which was closed in October 2019. Three patients achieved complete remissions (tumor marker and/or imaging studies), five achieved partial remissions, two developed disease progression (PD), and one was withdrawn after one cycle for severe paclitaxel neurotoxicity followed by rapid tumor progression and death. One patient with PD after one cycle had pathologically-confirmed metastatic transformation to pure embryonal rhabdomyosarcoma, and rapidly expired. A second patient, with pure pineal choriocarcinoma, progressed after the second GemPOx cycle, ultimately died of tumor progression. Eight of the 11 responsive patients subsequently underwent HDCx+AuHPCR; five of these received some form of radiotherapy. Seven patients (six MMGCT, one germinoma) are alive and disease-free without recurrence for a mean of 94 months (range 74–118 months) since completion of therapy. CONCLUSION: GemPOx is an effective re-induction regimen for patient with recurrent CNS germ cell tumors, with acceptable toxicities; when followed by marrow-ablative chemotherapy and subsequent irradiation/re-irradiation, the regimen produces encouraging long-term disease-free survival.

GCT-67. CENTRAL NERVOUS SYSTEM GERMINOMA IN TWO CAUCASIAN AMERICAN SIBLINGS WITH AUTISM SPECTRUM DISORDER

Stephanie Toll^{1,2}, and Hamza Gors^{1,2}; ¹Children's Hospital of Michigan, Detroit, MI, USA, ²Central Michigan University, Mount Pleasant, MI, USA

BACKGROUND: Central nervous system germ cell tumors (CNS-GCT) account for approximately 5% of all pediatric brain tumors. These tumors are pathologically heterogeneous, but have recurrent somatic mutations in KIT and rare germline variants in a Japanese cohort. Chromosomal abnormalities, specifically Klinefelter Syndrome, are associated with increased tumor development and familial cases have been reported, but no germline tumor syndromes are known. We describe a pair of siblings, both with autism spectrum disorder (ASD) that developed CNS-GCT, which previously has not been described outside of Japan. **CASES:** We report two siblings with ASD who developed CNS germinomas within two months of each other. The older brother, with basal ganglia and hypothalamic tumors, underwent surgical resection followed by treatment per ACNS0232 with chemotherapy and whole-ventricular irradiation (WVI). The younger sibling, with a mid-brain tumor, also received ACNS0232, but due to poor response required additional chemotherapy and WVI. Both siblings are without evidence of disease 7 years after end of therapy. Genetic testing, including chromosomal microarray, karyotyping, and whole genome sequencing did not elucidate any variant identified as causative at that time. **CONCLUSIONS:** CNS-GCT are rare tumors, diverse in both histopathologic diagnosis and clinical outcomes. Currently there are known somatic alterations and germline chromosomal disorders associated with increased tumor development, but no known inheritable causes. Despite this, familial CNS-GCT have been reported in patients of Japanese descent. The description of two Caucasian American siblings with ASD and CNS-GCT is novel, refuting that familial CNS-GCT are limited to the Japanese population.

GCT-69. VOLUMETRIC CHANGE BEFORE CHEMORADIOTHERAPY AND INFLUENCE OF DIAGNOSTIC RADIATION EXPOSURE IN INTRACRANIAL GERMINOMAS

Naoki Kagawa¹, Ryuichi Hirayama¹, Chisato Yokota^{1,2}, Yasuyoshi Chiba³, Yasunori Fujimoto⁴, Tomoyoshi Nakagawa¹, Toru Umehara¹, Noriyuki Kijima¹, Manabu Kinoshita¹, and Haruhiko Kishima¹; ¹Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Department of Neurosurgery, Suita Municipal Hospital, Osaka, Japan, ³Department of Neurosurgery, Osaka Women's and Children's Hospital, Osaka, Japan, ⁴Department of Neurosurgery, Osaka Rosai Hospital, Osaka, Japan

BACKGROUND: Spontaneous regression in intracranial germ cell tumors has been reported in some literatures, but the mechanism has not been well known. We retrospectively measured the tumor volume before chemoradiotherapy and analyzed factors that influence reduction of tumor volume. **PATIENTS AND METHODS:** Plural MRI scans were done before the first course of chemotherapy regimen in 27 patients with primary intracranial germinomas. Their age ranged from 8 to 31 years. 35 lesions from them were enrolled and included 13 pineal, 4 neurohypophyseal, 4 basal ganglia, 4 bifocal type, and 2 multiple lesions. All regions were verified as pure germinoma or HCG-producing germinoma by histopathological examination. Tumor volume of 35 lesions was analyzed by volumetric assessment based on MRI. Ratio of volumetric change between the first MRI and the scan immediately before chemotherapy was defined as shrinking rate (%). Period between disease onset and the first chemotherapy was 20 to 47 days. Diagnostic radiation dose was calculated in each case. **RESULTS:** Ini-

tial tumor volume ranged from 0.962 to 72.356 cubic centimeters (mean: 8.27). Diagnostic radiation dose: 40.5 to 910.1 mGy. Shrinking rate ranged from -57.8 to 85.4% (mean: 30.8). In 10 regions, shrinking rate was within 30%. Shrinking rate was significant positively influenced by diagnostic radiation dose ($p < 0.05$) and negatively influenced by initial volume ($p < 0.05$). But, other factors such as age, sex, histopathological parameters did not influence tumor shrinkage. **CONCLUSION:** This study shows that the volume of intracranial germ cell tumors is changing dynamically before chemoradiotherapy in many cases. Diagnostic exposure to low-dose radiation influences tumor shrinkage of intracranial germinomas.

GCT-70. INTRACRANIAL GROWING TERATOMA SYNDROME IN CHILDREN

Maria Carter Febres¹, Carol S. Bruggers¹, Holly Zhou¹, Arie Perry², John Kestle¹, and Nicholas Whipple¹; ¹University of Utah, Salt Lake City, Utah, USA, ²University of San Francisco, San Francisco, California, USA

Germ cell tumors account for less than 5% of all intracranial malignancies in children. Intracranial growing teratoma syndrome (GTS) is a rare pathophysiologic process characterized by growth of mature teratoma elements of a non-germinomatous germ cell tumor (NGGCT) during or following treatment with chemotherapy, in addition to normalization of or declining AFP/ β HCG of the cerebral spinal fluid (CSF)/serum. A 13-year-old male presented with headache, emesis, and diplopia. MRI of the brain/spine revealed a localized 3.1 x 3.1 x 3.2 cm pineal tumor. Biopsy confirmed NGGCT (germinoma, immature and mature teratoma). Serum AFP (227ng/ul) and β HCG (12 IU/L) and CSF AFP (21ng/ul) and β HCG (31 IU/L) were elevated. Prior to cycle two of chemotherapy, he developed unstable gait and moderate hearing loss. Repeat MRI brain demonstrated tumor enlargement (4.4 x 5.2 x 5.1 cm) and obstructive hydrocephalus, although serum AFP/ β HCG had normalized. Gross total resection of tumor confirmed GTS, without residual immature/malignant elements. Following six cycles of multiagent chemotherapy (carboplatin, etoposide, ifosfamide) and proton beam craniospinal irradiation (36 Gy with 18 Gy boost), he remains free of disease at eleven months since diagnosis. The pathogenesis of GTS remains unclear. Care must be taken to avoid misdiagnosing GTS as progressive NGGCT, as treatment and prognosis differ significantly. Second-look surgery, with a goal of complete resection, should be considered in cases of NGGCT when residual tumor grows during or following therapy, as this may represent GTS. Although histologically benign, GTS can be fatal. In patients with GTS, complete resection is usually curative.

GCT-71. SIOP STRATEGY TREATMENT FOR CENTRAL NERVOUS SYSTEM GERM CELL TUMORS IN A MIDDLE INCOME COUNTRY

Agustina Oller, Claudia Sampor, Lorena Baroni, Candela Freytes, Nicolas Fernandez Ponce, Gabriela Villanueva, and Daniel Alderete; Garrahan Hospital, Buenos Aires, Buenos Aires, Argentina

BACKGROUND/OBJECTIVES: Central nervous system (CNS) germ cell tumors (GCTs) represent 3% of primary paediatric brain tumours in incident. They can be divided into major groups including germinomas and nongerminomatous GCTs (NGGCTs). The aim is to describe demographic characteristics, Event Free Survival (EFS) and Overall Survival (OS) in patients with GCTs treated at Oncology Unit of Garrahan Hospital (HG). **DESIGN/METHODS:** Retrospective analysis of patients with GCTs admitted between September 1st, 2000 to September 1st, 2019. Variables analysed: age, localization, treatment, relapse and death. Patients were treated per SIOP-CNSGCTs protocol. For statistical analysis SPSS (IBM), for EFS/OS Kaplan-Meier, Long-rank for significance. **RESULTS:** Fifty-seven patients were included, comprising 38 Germinomas and 19 NGGCTs. Median age was 146 months (range 11–228). Primary site in localized Germinomas were pineal (16p), suprasellar (7p) and bifocal (7p). Five-year EFS and OS of 100% and 88.5%, respectively. Four patients presented metastatic disease, with an EFS and OS of 60.9% and 66.6%. Tumor site in localized NGGCT were pineal (8p) and suprasellar (5p). Five-year EFS was 81.8% and OS was 80.2%. No patients presented metastatic disease. All patients with high-risk tumor markers at diagnosis relapsed. No significant differences were found in OS neither EFS between groups (Germinomas OS5y 90% vs NGGCTs 74.6% $p = 0.19$ [CI95% 0.0786–1.689]), (Germinomas EFS5y 78.9% vs NGGCTs5y 81.8% $p = 0.85$ [CI95% 0.3046–4.230]). Global OS and EFS5y was 83% and 72.9%. **CONCLUSION:** OS of our cohort is lower than what has been shown in current literature. This result may be related to the lack of resources and lower social economic status in our population.

GCT-72. ANALYSIS OF MICRORNA EXPRESSION PROFILE OF INTRACRANIAL GERM CELL TUMORS: A PROMISING TOOL FOR DIFFERENTIAL DIAGNOSIS

Yoshiko Nakano¹, Kaishi Satomi^{2,1}, Hirokazu Takami^{1,3}, Ryo Nishikawa⁴, Fumiyuki Yamasaki⁵, Maehara Taketoshi⁶, Nobuhito Saito³, Yonehiro Kanemura⁷, Hiroaki Sakamoto⁸, Takahiro Ochiya^{9,10}, and Koichi Ichimura¹; ¹Division of Brain Tumor Translational Research,